{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:37:48Z","timestamp":1761197868900,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Suzhou Health Talents Training Project","award":["GSWS2019002"],"award-info":[{"award-number":["GSWS2019002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40263-020-00770-0","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T17:06:45Z","timestamp":1603818405000},"page":"1205-1215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Tao","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7036","authenticated-orcid":false,"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"issue":"3","key":"770_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/epi.12064","volume":"54","author":"R Sutter","year":"2013","unstructured":"Sutter R, Marsch S, Fuhr P, R\u00fcegg S. Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia. 2013;54(3):502\u201311.","journal-title":"Epilepsia."},{"issue":"13","key":"770_CR2","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","volume":"75","author":"E Trinka","year":"2015","unstructured":"Trinka E, H\u00f6fler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499\u2013521.","journal-title":"Drugs."},{"issue":"6","key":"770_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurology. 2015;14(6):615\u201324.","journal-title":"Lancet Neurology."},{"issue":"1","key":"770_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48\u201361.","journal-title":"Epilepsy Curr."},{"issue":"10231","key":"770_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","volume":"395","author":"JM Chamberlain","year":"2020","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. The Lancet. 2020;395(10231):1217\u201324.nn","journal-title":"The Lancet."},{"issue":"22","key":"770_CR6","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103\u201313.n","journal-title":"N Engl J Med."},{"issue":"3","key":"770_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ene.13560","volume":"25","author":"F Brigo","year":"2018","unstructured":"Brigo F, Bragazzi NL, Lattanzi S, Nardone R, Trinka E. A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. Eur J Neurol. 2018;25(3):451\u201363.nn","journal-title":"Eur J Neurol."},{"issue":"6","key":"770_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","volume":"22","author":"S Chakravarthi","year":"2015","unstructured":"Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959\u201363.nn","journal-title":"J Clin Neurosci."},{"issue":"10186","key":"770_CR9","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","volume":"393","author":"MD Lyttle","year":"2019","unstructured":"Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. The Lancet. 2019;393(10186):2125\u201334.nnn","journal-title":"The Lancet."},{"issue":"10186","key":"770_CR10","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","volume":"393","author":"SR Dalziel","year":"2019","unstructured":"Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. The Lancet. 2019;393(10186):2135\u201345.n","journal-title":"The Lancet."},{"issue":"7","key":"770_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","volume":"87","author":"S Nalisetty","year":"2020","unstructured":"Nalisetty S, Kandasamy S, Sridharan B, Vijayakumar V, Sangaralingam T, Krishnamoorthi N. Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus. Indian J Pediatr. 2020;87(7):512\u20139.","journal-title":"Indian J Pediatr."},{"issue":"10","key":"770_CR12","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","volume":"8","author":"G Wani","year":"2019","unstructured":"Wani G, Imran A, Dhawan N, Gupta A, Giri JI. Levetiracetam versus phenytoin in children with status epilepticus. J Family Med Prim Care. 2019;8(10):3367\u201371.n","journal-title":"J Family Med Prim Care."},{"issue":"11","key":"770_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3109\/00207454.2015.1095743","volume":"126","author":"UK Misra","year":"2016","unstructured":"Misra UK, Kalita J. A comparison of four antiepileptic drugs in status epilepticus: experience from India. Int J Neurosci. 2016;126(11):1013\u20139.","journal-title":"Int J Neurosci."},{"issue":"4","key":"770_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","volume":"15","author":"N Noureen","year":"2019","unstructured":"Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, et al. Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an Open-Label Randomized Controlled Trial. J Clin Neurol. 2019;15(4):468\u201372.n","journal-title":"J Clin Neurol."},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"3","key":"770_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","volume":"57","author":"V Vignesh","year":"2020","unstructured":"Vignesh V, Rameshkumar R, Mahadevan S. Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a Randomized Double-blind Controlled Clinical Trial. Indian Pediatr. 2020;57(3):222\u20137.nn","journal-title":"Indian Pediatr."},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","volume":"49","author":"AR Gujjar","year":"2017","unstructured":"Gujjar AR, Nandhagopal R, Jacob PC, Al-Hashim A, Al-Amrani K, Ganguly SS, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure. 2017;49:8\u201312.nn","journal-title":"Seizure."},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","volume":"114","author":"RC Mundlamuri","year":"2015","unstructured":"Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2014pilot study. Epilepsy Res. 2015;114:52\u20138.n","journal-title":"Epilepsy Res."},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.17511\/ijpr.2018.i04.13","volume":"5","author":"C Senthil Kumar","year":"2018","unstructured":"Senthil Kumar C, Selvakumar P, Kowsik M. Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epolepticus in children. Int J Pediatr Res. 2018;5:237\u201342.n","journal-title":"Int J Pediatr Res."},{"issue":"5","key":"770_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/jcm5050049","volume":"5","author":"JJ Falco-Walter","year":"2016","unstructured":"Falco-Walter JJ, Bleck T. Treatment of established status epilepticus. J Clin Med. 2016;5(5):49.","journal-title":"J Clin Med."},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.seizure.2018.05.012","volume":"68","author":"A Vasquez","year":"2019","unstructured":"Vasquez A, Farias-Moeller R, Tatum W. Pediatric refractory and super-refractory status epilepticus. Seizure. 2019;68:62\u201371.nn","journal-title":"Seizure."},{"issue":"Suppl 8","key":"770_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1528-1167.2011.03238.x","volume":"52","author":"S Shorvon","year":"2011","unstructured":"Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia. 2011;52(Suppl 8):53\u20136.","journal-title":"Epilepsia."},{"issue":"1","key":"770_CR23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-6723.2006.00807.x","volume":"18","author":"S Lewena","year":"2006","unstructured":"Lewena S, Young S. When benzodiazepines fail: how effective is second line therapy for status epilepticus in children? Emerg Med Australas. 2006;18(1):45\u201350.nnn","journal-title":"Emerg Med Australas."},{"issue":"8","key":"770_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1212\/01.wnl.0000180959.31355.92","volume":"65","author":"K Eriksson","year":"2005","unstructured":"Eriksson K, Mets\u00e4ranta P, Huhtala H, Auvinen A, Kuusela AL, Koivikko M. Treatment delay and the risk of prolonged status epilepticus. Neurology. 2005;65(8):1316\u20138.n","journal-title":"Neurology."},{"issue":"9","key":"770_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrneurol.2013.154","volume":"9","author":"R Sutter","year":"2013","unstructured":"Sutter R, Kaplan PW, R\u00fcegg S. Outcome predictors for status epilepticus\u2014what really counts. Nat Rev Neurol. 2013;9(9):525\u201334.","journal-title":"Nat Rev Neurol."},{"issue":"2","key":"770_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1528-1167.2009.02323.x","volume":"51","author":"J Novy","year":"2010","unstructured":"Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251\u20136.","journal-title":"Epilepsia."},{"issue":"1","key":"770_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jamaneurol.2013.578","volume":"70","author":"SE Hocker","year":"2013","unstructured":"Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70(1):72\u20137.","journal-title":"JAMA Neurol."},{"issue":"10","key":"770_CR28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1007\/s00134-017-4837-6","volume":"43","author":"AL Chateauneuf","year":"2017","unstructured":"Chateauneuf AL, Moyer JD, Jacq G, Cavelot S, Bedos JP, Legriel S. Super-refractory status epilepticus: epidemiology, early predictors, and outcomes. Intensive Care Med. 2017;43(10):1532\u20134.","journal-title":"Intensive Care Med."},{"issue":"12","key":"770_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1056\/NEJM199809173391202","volume":"339","author":"DM Treiman","year":"1998","unstructured":"Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"770_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/08830738050200060201","volume":"20","author":"JC Brevoord","year":"2005","unstructured":"Brevoord JC, Joosten KF, Arts WF, van Rooij RW, de Hoog M. Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. J Child Neurol. 2005;20(6):476\u201381.n","journal-title":"J Child Neurol"},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.seizure.2020.03.002","volume":"78","author":"L Li","year":"2020","unstructured":"Li L, Zhang Y, Jia L, Jia D, Faramand A, Chong W, et al. Levetiracetam versus phenytoin for the treatment of established status epilepticus: a systematic review and meta-analysis of randomized controlled trials. Seizure. 2020;78:43\u20138.n","journal-title":"Seizure"},{"issue":"Pt B","key":"770_CR32","doi-asserted-by":"publisher","first-page":"106466","DOI":"10.1016\/j.yebeh.2019.106466","volume":"101","author":"F Brigo","year":"2019","unstructured":"Brigo F, Del Giovane C, Nardone R, Trinka E, Lattanzi S. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis. Epilepsy Behav. 2019;101(Pt B):106466.nn","journal-title":"Epilepsy Behav"},{"issue":"13","key":"770_CR33","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","volume":"75","author":"E Trinka","year":"2015","unstructured":"Trinka E, Hofler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499\u2013521.nnn","journal-title":"Drugs."},{"issue":"1","key":"770_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2125.2003.01829.x","volume":"56","author":"BR Ogutu","year":"2003","unstructured":"Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Edwards G, Watkins WM, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol. 2003;56(1):112\u20139.","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"770_CR35","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1528-1167.2011.03056.x","volume":"52","author":"V Alvarez","year":"2011","unstructured":"Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292\u20136.n","journal-title":"Epilepsia."},{"issue":"1","key":"770_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4067\/S0034-98872016000100011","volume":"144","author":"LC Vargas","year":"2016","unstructured":"Vargas LC, Varela EX, Kleinsteuber SK, Cort\u00e9s ZR, Avaria BML. Management of pediatric status epilepticus [in Spanish]. Rev Med Chil. 2016;144(1):83\u201393.","journal-title":"Rev Med Chil."},{"issue":"8","key":"770_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-019-00652-0","volume":"33","author":"F Brigo","year":"2019","unstructured":"Brigo F, Lattanzi S, Nardone R, Trinka E. Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33(8):771\u201381.n","journal-title":"CNS Drugs"},{"key":"770_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","volume":"86","author":"F Brigo","year":"2018","unstructured":"Brigo F, Lattanzi S, Rohracher A, Russo E, Meletti S, Grillo E, et al. Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav. 2018;86:179\u201386.","journal-title":"Epilepsy Behav."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00770-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:31:12Z","timestamp":1696962672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00770-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00770-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"1 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Suzhou Health Talents Training Project (GSWS2019002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tao Xue, Luxin Wei, Xiaotian Shen, Zilan Wang, Zhouqing Chen, and Zhong Wang declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ZW and ZC were the principal investigators. TX and LW designed the study and developed the analysis plan; analyzed the data and performed the meta-analysis; and contributed to the writing of the article. XS and ZW revised the manuscript and polished the language. All authors read and approved the final submitted paper.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}